Skip to main content
Fig. 3 | Clinical Proteomics

Fig. 3

From: The novel biomarkers for assessing clinical benefits of continuous renal replacement therapy in pediatric sepsis: a pilot study

Fig. 3

Confirmed analysis of serum candidates including LYZ, LRG1, FMOD, SERPINA3, SELL, and CD14 using ELISA in the validation set. A, B serum LYZ levels, C, D serum LRG1 levels, E, F serum FMOD levels, G, H serum SEPRINA3 levels, I, J serum SELL levels, K, L serum CD14 levels. * indicates P < 0.05. ** indicates P < 0.01. ***indicates P < 0.001

Back to article page

Clinical Proteomics

ISSN: 1559-0275